Physician profile
Andrew Ninichuck
NPI 1609841956
$6,584.98
in general payments reported to CMS, 2019-2025
41 companies · $427 in 2025
The $427 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $882 · 2021: $1,569 · 2022: $1,422 · 2023: $590 · 2024: $677 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,550.61 | 2021-2025 | |
| Allergan, INC. | $622.44 | 2019-2020 | |
| Lilly USA, LLC | $621.21 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $485.24 | 2019-2022 | |
| Amgen INC. | $284.66 | 2019-2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.91 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $140.19 | 2019-2023 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.47 | 2019-2021 | |
| Pfizer INC. | $116.73 | 2019-2024 | |
| Novo Nordisk INC | $111.89 | 2021-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $96.09 | 2019-2024 | |
| Glaxosmithkline, LLC. | $87.58 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $83.29 | 2024-2025 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $80.35 | 2019 | |
| Indivior INC. | $74.01 | 2022-2024 | Perseris |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ninichuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.